Rapport Therapeutics, Inc. (RAPP)

Rapport Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022
Selling, General & Admin	8.18	1.25
Research & Development	28	4.12
Other Operating Expenses	0	5
Operating Expenses	36.18	10.37
Operating Income	-36.18	-10.37
Interest Expense / Income	0	0.29
Other Expense / Income	-1.4	-
Pretax Income	-34.78	-10.65
Income Tax	0.01	0
Net Income	-34.79	-10.65
Shares Outstanding (Basic)	13	7
Shares Outstanding (Diluted)	13	7
Shares Change	93.74%	-
EPS (Basic)	-2.70	-1.60
EPS (Diluted)	-2.70	-1.60
Free Cash Flow	-28.82	-3.53
Free Cash Flow Per Share	-2.23	-0.53
EBITDA	-34.46	-10.35
Depreciation & Amortization	0.32	0.02
EBIT	-34.78	-10.37

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).